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Abstract
Abnormal riboflavin status in the absence of a dietary deficiency was
detected in 31 consecutive outpatients with Parkinson’s disease (PD),
while the classical determinants of homocysteine levels (B6, folic
acid, and B12) were usually within normal limits. In contrast, only 3 of
10 consecutive outpatients with dementia without previous stroke had
abnormal riboflavin status. The data for 12 patients who did not
complete 6 months of therapy or did not comply with the proposed
treatment paradigm were excluded from analysis. Nineteen PD pa-
tients (8 males and 11 females, mean age ± SD = 66.2 ± 8.6 years; 3,
3, 2, 5, and 6 patients in Hoehn and Yahr stages I to V) received
riboflavin orally (30 mg every 8 h) plus their usual symptomatic
medications and all red meat was eliminated from their diet. After 1
month the riboflavin status of the patients was normalized from 106.4
± 34.9 to 179.2 ± 23 ng/ml (N = 9). Motor capacity was measured by
a modification of the scoring system of Hoehn and Yahr, which
reports motor capacity as percent. All 19 patients who completed 6
months of treatment showed improved motor capacity during the first
three months and most reached a plateau while 5/19 continued to
improve in the 3- to 6-month interval. Their average motor capacity
increased from 44 to 71% after 6 months, increasing significantly
every month compared with their own pretreatment status (P < 0.001,
Wilcoxon signed rank test). Discontinuation of riboflavin for several
days did not impair motor capacity and yellowish urine was the only
side effect observed. The data show that the proposed treatment
improves the clinical condition of PD patients. Riboflavin-sensitive
mechanisms involved in PD may include glutathione depletion, cumu-
lative mitochondrial DNA mutations, disturbed mitochondrial protein
complexes, and abnormal iron metabolism. More studies are required
to identify the mechanisms involved.
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Introduction
During absorption of riboflavin, flavoki-
nase phosphorylates the vitamin to yield fla-
vin mononucleotide (FMN) that, according
to the cellular requirements, is transformed
into flavin-adenine dinucleotide (FAD) by
FAD synthase (1,2). Progressive deficiency
of riboflavin is associated with co-factor loss
in a controlled manner, apparently ensuring
that essential catalytic activity such as that
related to aerobic metabolism is preserved
(3,4).
Low riboflavin status may also result
from defective absorption. In spite of an
adequate dietary intake of riboflavin (FAD,
vitamin B2), 10-15% of the inhabitants of
London and of Florence present low activi-
ties of two riboflavin-dependent enzymes -
erythrocyte glutathione reductase (EGR) and
pyridoxin(pyridoxamine)-phosphate oxidase
(5). The activity of both enzymes was cor-
rected by adding their respective co-factors
(FAD or FMN) to a test tube assay or by
administering high doses of riboflavin (24-
30 mg per day for 5-8 weeks) to the affected
individuals (6). The dependency of both FMN
and FAD levels on riboflavin absorption
(i.e., on flavokinase activity), and the nor-
malization of the activities of both FMN-
and FAD-dependent enzymes only at a high
riboflavin intake, taken together, are consist-
ent with the expression of flavokinase iso-
forms with low affinity for the substrate -
riboflavin (5). Anderson et al. (5) suggested
that the relatively large percent of persons
with altered riboflavin absorption (10-15%)
may reflect the situation in the world popula-
tion rather than being a feature of a particular
ethnic group.
Low EGR activity may explain glutathi-
one depletion with impaired antioxidant de-
fense, the earliest neurochemical abnormal-
ity in Parkinson’s disease (PD), already ob-
served in the substantia nigra before the
disorder becomes clinically evident (7).
Moreover, the reduced bioavailability of
FMN and/or FAD may also explain the im-
paired oxidative metabolism of PD patients
(8-10).
The first objective of the present study
was to determine the status of riboflavin in
PD patients. The second was to evaluate the
specificity of the alterations of riboflavin
status for PD by measuring the levels of
vitamin B2 and of other determinants of
homocystinemia (vitamins B6, B12, and folic
acid) in PD patients and comparing them
with those of individuals with dementia (11-
13). Third, we also determined the effect of
normalization of riboflavin status on the
motor capacity of PD patients. Part of the
data reported here, obtained during the first
3 months of treatment, were reported at the
6th International Conference on Parkinson’s
and Alzheimer’s Diseases (14).
Patients and Methods
This study was approved by the Ethics
Committee for Clinical Research of the Hos-
pital do Servidor Público Municipal de São
Paulo (HSPM) and informed consent was
obtained from all participants or persons
responsible for them.
The diagnosis of sporadic PD was made
according to current criteria (15) with spe-
cial care taken to exclude confounding dis-
orders, particularly in the early stages of the
disease.
Vitamin and homocysteine determina-
tions were performed on 31 sporadic PD
patients (67.5 ± 9.3 years old, 13 males and
18 females): 3, 3, 3, 8, and 14 patients were
assigned, early in the morning, to stages I to
V of Hoehn and Yahr (16), respectively.
Ten individuals (77.5 ± 8.8 years old, 5
males and 5 females) with dementia without
stroke (DwoSt) and a low Mini-Mental score
(13) were used as the control group for blood
chemistry. They had no history of stroke or
evidence for ischemic lesions of the brain by
CT or NMRI and had been consecutively
attended in the Neurology Clinic of HSPM.
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Blood samples were obtained after a 10-
to 12-h fast for serum assays of vitamin B12
by electrochemiluminescence immunoassay
(11820753 Roche Diagnostics GmbH, Mann-
heim, Germany) and of homocysteine by
HPLC (17). Heparinized plasma was assayed
for FAD (18), vitamin B6 (19), and folic acid
(20) by HPLC, as well as for the determina-
tion of the EGR-activation coefficient (EGR-
AC) (21) in red blood cell lysates (22).
  A food questionnaire covered the weekly
dietary habits of all PD and DwoSt patients
from 5 years prior to the onset of PD until the
appearance of spontaneous changes associ-
ated with the onset of chewing and/or swal-
lowing impairment or until the medical in-
terview in the absence of these impairments.
The questionnaire also evaluated the ad-
equacy of daily vitamin intake.
All PD patients received 30 mg riboflavin
orally at about 8-h intervals (90 mg/day) and
their usual symptomatic medications. This
dosage was used to avoid decreased absorp-
tion associated with higher doses or shorter
intervals between administrations. Due to the
renal excretion of riboflavin (3), the treatment
was only initiated after confirmation of nor-
mal blood levels of creatinine (0.5-1.4 mg/dl).
Because the PD patients had a higher con-
sumption of red meat (beef and pork) than sex-
matched controls (19 healthy non-consanguin-
eous relatives or neighbors of similar age re-
cruited for controlling the dietary habits), all
PD patients were required to eliminate all red
meat from their diets. The symptomatic drugs
for PD in use included L-DOPA with carbidopa
(200/50 mg tablets), L-DOPA with benserazide
hydrochloride (200/50 mg tablets), biperiden
(2 or 4 mg tablets), amantadine hydrochloride
(100 mg tablets), selegiline (5 mg tablets), and
pramipexole (0.25 or 1.0 mg tablets) taken
alone or in diverse combinations. The treat-
ment paradigm with symptomatic drugs for
PD for each patient when the study began
was maintained.
The motor capacities of the 19 PD pa-
tients who complied with the proposed treat-
ment for 6 months by early August 2003
were rated monthly according to a motor
function scale (Table 1), and compared with
their own pretreatment values. The scale
was based on that of Hoehn and Yahr (16)
and new categories were added in order to
detect subtle changes in the patients’ motor
capacity. In addition, the presence or ab-
sence of responses to symptomatic drugs for
PD is also used for more accurate character-
ization of the residual motor capacity of PD
patients (for instance, compare the descrip-
tions corresponding to 0 and 15% of motor
capacity, Table 1). Although there are no
direct validation studies of this rating sys-
tem, the different levels of motor capacity in
Table 1 represent a simple increase in the
number of components within stages I to V
of the widely employed Hoehn and Yahr
system (16).
After the first month of treatment, com-
pliance with the dietary directions and vita-
min intake was determined in all patients,
and the fasting plasma levels of FAD and
EGR-AC values were re-evaluated in 9 of
them approximately 9-12 h after the latest
riboflavin dose.
The blood chemistry data obtained from
both groups were compared statistically by
the Student t-test and the motor function data
were analyzed statistically by the Wilcoxon
signed rank test, with the level of signifi-
cance set at P < 0.05.
Results
Diversified food intake, including daily
ingestion of milk, which is particularly rich
in vitamin B2, was confirmed in all patients,
with PD patients frequently declaring a strong
preference for red meat. The content of the
daily family meals was usually adapted to
meet the high demand for red meat of most
PD patients. In contrast, all 10 DwoSt pa-
tients passively accepted the family diet. The
estimated red meat consumption prior to the
onset of impaired chewing/swallowing by
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19 PD patients (8 males and 11 females,
mean age ± SD = 66.2 ± 8.6 years) at lunch
and dinner within a 7-day period was signifi-
cantly higher (mean consumption = 2,044 ±
1,439 g/week, range = 0-5,100 g/week) than
that of their 19 diet controls (8 males and 11
females, all healthy individuals of similar
social and cultural background, recruited
among non-consanguineous relatives and
neighbors of PD patients of similar age;
mean age = 64.6 ± 11.3 years, mean con-
sumption = 789 ± 509 g/week, range = 150-
1800 g/week; P < 0.01, Mann-Whitney
U-test). The calorie intake did not differ
significantly between the two groups.
The basal plasma concentrations of FAD
of the PD patients (100.9 ± 22 ng/ml) were
significantly lower than those observed in
the patients with DwoSt (128.8 ± 25.6 ng/ml,
P < 0.01, Student t-test) while other determi-
nants of homocysteine levels (pyridoxine,
folic acid, and methylcobalamin) were usu-
ally within normal limits, and did not differ
significantly between the two groups (Table
2). The PD group also had significantly higher
EGR-AC levels than DwoSt patients (1.43 ±
Table 2. Vitamins and homocysteine levels in patients with Parkinson’s disease (N = 31) and dementia without
stroke (N = 10).
Group Riboflavin EGR-AC Pyridoxine Folic acid Vitamin Homocysteine
(ng/ml) (nmol/l) (ng/ml) B12 (pg/ml) (µmol/l)
Normal range 125-300 1.00-1.20 28-210 2-12 200-900 <15
PD 100.9 ± 22.0* 1.43 ± 0.26* 25.3 ± 6.1 5.6 ± 4.0 356.0 ± 261.0 12.1 ± 6.8
DwoSt 128.8 ± 25.6 1.20 ± 0.11 24.3 ± 9.4 4.3 ± 2.8 440.7 ± 322.5 13.1 ± 4.6
The first entry in the table is the normal value for each compound. DwoSt = dementia without stroke; EGR-AC
= erythrocyte glutathione reductase-activation coefficient; PD = Parkinson’s disease. PD and DwoSt data are
reported as mean ± SD.
*P < 0.01 for PD compared to DwoSt (Student t-test).
Table 1. Rating system of residual motor capacity of Parkinson’s disease patients based on Hoehn and Yahr
(16).
% Motor Description
capacity
0 Requires assistance to stand even on SD for PD.
15 Stands while on SD for PD but still requires assistance for most or all basic care.
30 Stands unassisted prior to the early morning SD for PD but still needs assistance for
some basic care while on SD for PD.
50 Unassisted basic care and reduced unsteadiness while on SD for PD.
65 Unassisted basic care prior to the early morning SD for PD; improved balance while on
SD for PD.
80 Bilateral rigidity/tremor + midline changes with normal balance prior to the early morning
SD for PD; continuous but reduced symptoms while on SD for PD.
90 Unilateral continuous rigidity/tremor prior to the early morning SD for PD; markedly reduced
or absent symptoms/signs while on SD for PD.
95 Mild unilateral intermittent rigidity/tremor (mostly under stress) without SD for PD + fully
asymptomatic while on SD for PD.
100 Fully asymptomatic without SD for PD.
The categories of Hoehn and Yahr (16) were expanded in order to detect subtle changes in the patients’
motor capacity with time, as well as to include the responsiveness to symptomatic drugs (SD) for Parkinson’s
disease (PD), while reporting the results in percent.
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0.26 vs 1.20 ± 0.11, respectively, P < 0.01,
Student t-test).
It is important to point out that all 31 PD
patients (including 3 newly diagnosed indi-
viduals not on symptomatic drugs for PD)
but only 3 of 10 DwoSt patients had low
plasma riboflavin levels. Normalization of
the plasma concentrations of riboflavin and
EGR-AC values was confirmed after 1 month
of treatment (from 106.4 ± 34.9 to 179.2 ±
23.0 ng/ml, and from 1.40 ± 0.25 to 1.11 ±
0.08, N = 9, respectively).
About 10 to 15 days after the beginning
of high-dose riboflavin treatment, PD pa-
tients often reported better (progressively
less interrupted) sleep at night, improved
reasoning, higher motivation, and reduced
depression. Their family members usually
started noticing motor improvements after
20 days of treatment, but in some cases of
advanced disability the patient was able to
change body position in bed at night as early
as on the third day of treatment.
By the time of writing this report in Au-
gust 2003, 19 PD patients (respectively, 3, 3,
2, 5, and 6 patients initially rated as stages I
to V of Hoehn and Yahr (16)) had completed
6 months of treatment with riboflavin ad-
ministration and dietary red meat elimina-
tion. The data in Figure 1A show that all of
them improved their motor capacity during
the first 3 months and most reached a pla-
teau, while 5/19 continued to improve in the
3- to 6-month interval. Figure 1B shows that
the average motor capacity for these 19 pa-
tients increased from 44 to 71%. Their motor
capacity increased significantly during the
first month and every month for the next 5
months of treatment compared with their
own pretreatment status, demonstrating a
progressive and marked improvement (P <
0.001, Wilcoxon signed rank test). The rate
of motor recovery was higher in the first 3
months than in the last 3 months of treat-
ment. No patient on high doses of riboflavin
reported adverse effects.
Because they could stand and walk with
improved (although still altered) balance by
2 months of treatment, two male patients
(initially in stage V (16) with associated
dementia and hallucinations) started striking
imaginary persons and/or often attempted to
leave home unaccompanied, reacting aggres-
sively against the relative who tried to stop
them. These episodes of agitation and ag-
gressiveness were observed less often by the
end of the third month of riboflavin treat-
ment and disappeared thereafter, but caused
transient concern and distress among their
family members who initially regarded them
as signs of neurological worsening.
Three patients (2 individuals initially in
stage II and 1 in stage I of Hoehn and Yahr
(16)) reached 100% motor capacity within
the first 3 months of treatment (Figure 1A).
Four patients had run out of riboflavin tab-
lets for up to 7 days between two consecu-
tive clinical appointments, but sustained the
benefit already achieved by then.
Twelve of 31 patients initially assessed
for riboflavin status who either did not com-
plete 6 months of therapy or did not comply
with the proposed treatment paradigm were
excluded from statistical analysis.
Discussion
This study demonstrated a progressive and
marked improvement of motor capacity in
consecutively evaluated patients with sporadic
PD who started with below normal laboratory
indexes of riboflavin and who eliminated red
meat from their diets while receiving high
multiple daily doses of riboflavin over a
period of 6 months while taking their usual
symptomatic medications. The mean motor
capacity of a group of 19 PD patients showed
a progressive 50% recovery over a period of
only 3 months - a most surprisingly high and
fast improvement, considering that about
60% of nigral neurons have already been lost
at the onset of manifestations of PD (15).
The initial riboflavin status was low in all
31 consecutively evaluated PD individuals,
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and significantly lower in PD patients com-
pared with those with another neurodegen-
erative disease also associated with hyper-
homocystinemia (DwoSt), suggesting that
abnormal riboflavin status may be a specific
feature of PD rather than a minor metabolic
contributor to the degeneration of nigral neu-
rons. Taken together with the rapid and pro-
found neurological improvement associated
with normalization of riboflavin status, this
observation suggests that altered riboflavin
status may be a cause of neurodegeneration
in PD.
Although urinary excretion of riboflavin
peaks within 1-2 h and returns to baseline
within 5-6 h after a large oral dose (3), the
benefit achieved did not vanish in four PD
patients over a therapeutic interval of up to 7
days. This observation suggests the occur-
rence of steady plastic changes rather than a
pharmacological effect of high-dose ribofla-
vin treatment to account for the improved
motor capacity shown in Figure 1. The steady
build-up of the motor recovery observed
during the first 3 months of treatment sug-
gests that this treatment paradigm may inac-
tivate fundamental neurodegenerative
mechanisms (e.g., glutathione depletion, con-
sidered to be an early key event in the patho-
genesis of PD (23,24)), possibly allowing
regenerative plastic phenomena to occur.
The importance of the elimination of di-
etary red meat for the results reported here is
not known. The content of vitamin B2 in
meat in general is considerable (about 0.2
mg/100 g), and diverse cooking procedures
cause only minor (7-18%) loss of this micro-
nutrient (25). The daily requirement for indi-
viduals above the age of 14 years is ≤1.3 mg/
day. Therefore, if the PD patients had a
normal absorptive capacity for vitamin B2,
their large ingestion of red meat (up to 700 g/
day), associated with milk, rice and beans,
fruits and vegetables, should have provided
a normal riboflavin status. In contrast, 31
consecutive PD patients had laboratory evi-
dence for riboflavin deficiency (Table 2)
suggesting that patients with sporadic PD
belong to the subset of the general popula-
tion (10-15%) (3) that may express a
flavokinase with low affinity for vitamin B2,
leading to a decreased absorption.
However, the digestion of red meat re-
leases hemin, a highly diffusible toxin that,
when not properly inactivated, increases in-
tracellular iron concentrations and enhances
hydroxyl radical production (Fenton reac-
tion). Most of the absorbed hemin is de-
stroyed by the enzyme heme oxygenase (HO)
in the digestive tract and liver (26). Because
HO is oxidized during the catabolization of
hemin to biliverdin, the HO molecules must
be reduced through the coordinated activity
of the flavoenzyme cytochrome P450 reduc-
tase for continued hemin inactivation (Fig-
ure 2) (27). Cytochrome P450 reductase is
Figure 1. Motor capacity of patients with Parkinson’s disease who received 30 mg ribofla-
vin/8 h, orally (240 mg/day) and abstained from dietary red meat for 6 months. Motor
capacity was evaluated monthly for each patient by a modification of the method of Hoehn
and Yahr (16) to provide a score in percent (Table 1). A, Individual data for the evolution of
motor capacity of 19 patients for 0 to 3 and 3 to 6 months of treatment. *P < 0.001 for
values at 3 months (month 0) compared with those before treatment; **P < 0.05 for values
at 6 months compared with those obtained at 3 months (Wilcoxon signed rank test). B, The
height of the columns indicates the mean motor capacity values (see Table 1) after the
indicated periods of treatment. When compared with their own basal levels (month 0),
highly significant and progressively higher differences were observed for each consecutive
month of treatment. *P < 0.001 (Wilcoxon signed rank test).
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particularly sensitive to riboflavin deficiency
because it requires both FMN and FAD as
prosthetic groups (28). It is possible that
individuals with decreased absorption of vi-
tamin B2 may not completely inactivate high
dietary levels of hemin, allowing this neuro-
toxic compound to reach the brain cells.
Consistently, the staining for HO-1 isozyme
is increased in astrocytes and reacts with
neuronal Lewy bodies in the nigra of PD
patients, suggesting that its overexpression
may contribute to the pathological iron depo-
sition and mitochondrial damage in PD (29).
By binding glutathione (30) hemin may fur-
ther decrease glutathione levels in the brains
of PD patients through a direct mechanism.
Because humans lack efficient iron ex-
cretory mechanisms, iron excess is dealt with
by increasing the synthesis of the iron-stor-
age protein ferritin (31). Disturbed systemic
(32) and brain (33) iron metabolism has
been reported in PD, suggesting that a selec-
tive decrease in the levels of ferritin may
result in an increase in intracellular free iron,
thereby enhancing free radical production
(34). Indeed, vitamin B2 deficiency in ro-
dents is associated with low circulating iron
concentrations, increased iron turnover and
excretion into the intestinal lumen, which
may occur in response to impaired ferritin
synthesis (35,36). Therefore, the consistent
finding of an abnormal riboflavin status in
PD, as reported here, may help to explain the
disturbed iron metabolism found in PD pa-
tients, with the underlying mechanisms pos-
sibly involving impaired hemin catabolism
and reduced ferritin synthesis. Interestingly,
the highest world prevalence of PD is found
among the inhabitants of Buenos Aires (37),
where the consumption of red meat is tradi-
tionally high. Similarly, the identification of
high dietary animal fat as a risk factor for PD
(37) may actually reflect a role of high di-
etary hemin in PD pathology.
Moreover, because FAD is required in
the two alternative pathways of deoxynucleo-
tide synthesis (2), DNA repair and replica-
tion are expected to be disturbed upon de-
creased bioavailability of riboflavin, and
abnormal riboflavin status may also explain
the cumulative mitochondrial DNA muta-
tions reported in PD (38).
The present results with 19 PD patients
who showed a significant improvement in
motor function after treatment with ribofla-
vin and the elimination of red meat from the
diet suggest that an abnormal riboflavin sta-
tus, possibly due to flavokinase deficiency,
may be an essential requirement for trigger-
ing and sustaining the degeneration of dopa-
minergic neurons in PD. As a result of the
reduced B2 bioavailability, ATP production
is selectively preserved, while the less criti-
cal FAD- or FMN-dependent metabolic path-
ways are impaired (4). Consequently, free
iron concentrations in the cytosol increase as
a result of impaired ferritin synthesis and/or
reduced hemin catabolism associated with
hydrogen peroxide accumulation due to glu-
tathione depletion, thereby triggering the
Fenton reaction and ultimately leading to the
selective formation of the potent neurotoxin
6(OH)DA in dopaminergic neurons.
Current concepts about the cause of spo-
radic PD suggest an inherited predisposition
to environmental or endogenous toxic agents
(39), and the data presented and reviewed
here suggest that flavokinase deficiency
should be considered in future research as a
Figure 2. Dependency of hemin catabolism on riboflavin bioavailability. The elimination of
hemin requires cyclic reduction of heme oxygenase by flavoprotein cytochrome P450
reductase that, in turn, utilizes both flavin mononucleotide (FMN) and flavin-adenine
dinucleotide (FAD) as prosthetic groups. Average or increased red meat consumption may
overload the capacity of this chain of reactions already compromised by impaired intestinal
absorption of riboflavin (with decreased FMN and FAD synthesis), leading to increased
hemin (iron) delivery to the CNS and increased utilization of riboflavin for hemin inactiva-
tion. Modified from Figure 1, box 21-1, page 783 of Ref. 2.
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promising candidate to account for this in-
herited predisposition, while dietary factors
such as red meat consumption may largely
account for the environmental/endogenous
toxicity. The administration of high doses of
riboflavin combined or not with red meat
elimination may be an effective therapeutic
paradigm addressing the determinants of PD,
capable of providing regression to earlier
clinical stages, or even to the nonsymptomatic
state without symptomatic drugs for PD (at
least in some cases), rather than only disease
stabilization or partial symptomatic relief.
Although the relentless progression of
PD clearly contrasts with the results of the
treatment paradigm reported here, a larger
and more prolonged study is certainly re-
quired to document the steadiness and the
full extent of the ongoing recovery. A scien-
tifically desirable blinded clinical trial with a
placebo would necessarily leave known ri-
boflavin-deficient patients untreated for a
long period of time, when their neurological
disability may progress as a consequence of
sustained loss of nigral neurons, possibly
rendering the ultimate response to delayed
normalization of their riboflavin levels less
complete. Therefore, the need for controlled
trials should be weighed ethically consider-
ing the contrast of the natural history of PD
(progress of motor disability to death despite
an increase in the efficacy of symptomatic
drugs for PD treatment) with the outcome of
the vitamin B2 treatment observed in larger
and more prolonged studies without con-
trols.
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